GSK going nowhere while key vaccines struggle, says US bank
Portfolio Pulse from
Jefferies has downgraded GSK's investment rating to 'hold' due to concerns about its key vaccines, despite recent positive news.
November 12, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jefferies downgraded GSK to 'hold' due to concerns over its vaccines Shingrix and Arexvy, overshadowing recent positive news.
Jefferies' downgrade reflects concerns about GSK's key vaccines, which are significant to its business. This downgrade is likely to negatively impact GSK's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100